Table 2. Association between clinicopathologic features and survival or expression level of TSP50, p53 or CEA in CRCs.
| Variables | Cases | Survival P (log-rank) | TSP50 expression (%) | p53 expression (%) | CEA expression (%) | ||||||
| Low | High | P (χ2) | Low | High | P (χ2) | Low | High | P (χ2) | |||
| Total number of patients | 95 | 30 (31.6) | 65 (68.4) | 62 (65.3) | 33 (34.7) | 40 (42.1) | 55 (57.9) | ||||
| Age group, y | |||||||||||
| ≤56 | 47 | 0.727 | 19 (40.4) | 28 (59.6) | 0.066 | 32 (68.1) | 15 (31.9) | 0.568 | 23 (48.9) | 24 (51.1) | 0.182 |
| >56 | 48 | 11 (22.9) | 37 (77.1) | 30 (62.5) | 18 (37.5) | 17 (35.4) | 31 (64.6) | ||||
| Sex | |||||||||||
| Women | 40 | 0.301 | 13 (32.5) | 27 (67.5) | 0.869 | 25 (62.5) | 15 (37.5) | 0.630 | 17 (42.5) | 23 (57.5) | 0.947 |
| Men | 55 | 17 (30.9) | 38 (69.1) | 37 (67.3) | 18 (32.7) | 23 (41.8) | 32 (58.2) | ||||
| Tumor location | |||||||||||
| Colon | 40 | 0.450 | 9 (22.5) | 31 (77.5) | 0.104 | 31 (77.5) | 9 (22.5) | 0.033 | 16 (40.0) | 24 (60.0) | 0.723 |
| Rectum | 55 | 21 (38.2) | 34 (61.8) | 31 (56.4) | 24 (43.6) | 24 (43.6) | 31 (56.4) | ||||
| Tumor size, cm | |||||||||||
| ≤4 | 50 | 0.602 | 16 (32.0) | 34 (68.0) | 0.926 | 29 (58.0) | 21 (42.0) | 0.117 | 21 (42.0) | 29 (58.0) | 0.983 |
| >4 | 45 | 14 (31.1) | 31 (68.9) | 33 (73.3) | 12 (26.7) | 19 (42.2) | 26 (57.8) | ||||
| Depth of invasion | |||||||||||
| T2 | 20 | 0.080 | 4 (20.0) | 16 (80.0) | 0.174 | 15 (75.0) | 5 (25.0) | 0.566 | 9 (45.0) | 11 (55.0) | 0.305 |
| T3 | 44 | 18 (40.9) | 26 (59.1) | 27(61.4) | 17 (38.6) | 15 (34.1) | 29 (65.9) | ||||
| T4 | 31 | 8 (25.8) | 23 (74.2) | 20 (64.5) | 11 (35.5) | 16 (51.6) | 15 (48.4) | ||||
| Lymph node metastasis | |||||||||||
| N0 | 55 | <0.0001 | 18 (32.7) | 37 (67.3) | 0.862* | 35 (63.6) | 20 (36.4) | 0.569* | 27 (49.1) | 28 (50.9) | 0.157 |
| N1 | 26 | 7 (26.9) | 19 (73.1) | 19 (73.1) | 7 (26.9) | 10 (38.5) | 16 (61.5) | ||||
| N2 | 14 | 5 (35.7) | 9 (64.3) | 8 (57.1) | 6 (42.9) | 3 (21.4) | 11 (78.6) | ||||
| Tumor stage | |||||||||||
| I | 14 | <0.0001 | 3 (21.4) | 11 (78.6) | 0.798* | 12 (85.7) | 2 (14.3) | 0.238* | 6 (42.9) | 8 (57.1) | 0.413* |
| II | 41 | 15 (36.6) | 26 (63.4) | 23 (56.1) | 18 (43.9) | 21 (51.2) | 20 (48.8) | ||||
| III | 29 | 9 (31.0) | 20 (69.0) | 20 (69.0) | 9 (31.0) | 10 (34.5) | 19 (65.5) | ||||
| IV | 11 | 3 (27.2) | 8 (72.8) | 7 (63.6) | 4 (36.4) | 3 (27.3) | 8 (72.7) | ||||
| Tumor grade | |||||||||||
| Low | 75 | 0.022 | 22 (29.3) | 53 (71.7) | 0.362 | 47 (62.7) | 28 (37.3) | 0.303 | 27 (36.0) | 48 (64.0) | 0.020 |
| High | 20 | 8 (40.0) | 12 (60.0) | 15 (75.0) | 5 (25.0) | 13 (65.0) | 7 (35.0) | ||||
Median values were used as cut-off points for definition of subgroups (age group and tumor size).
*Fisher's Exact Test.
TSP50, testes-specific protease 50; CRC, colorectal carcinoma; CEA, carcinoembryonic antigen.